Clinical trial
A Phase II Study of MK-2206 for Recurrent Malignant Glioma
NCT01249105 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of MK-2206 for Recurrent Malignant Glioma
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- 0 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
malignant glioma